Kevin David

10PUBLICATIONS

94CO-AUTHORS

Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPredictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (10)

Sort by Publication Date:

|Jul 10, 2026

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

|Jun 30, 2026

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

|Feb 09, 2026

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

Catherine Diefenbach, Opeyemi Jegede, Victoria Wang

|Mar 26, 2024

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.

Reem Karmali, Rushad Machhi, Narendranath Epperla

|Mar 18, 2024

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.

Megan Melody, Narendranath Epperla, Geoffrey Shouse

|Aug 21, 2023

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.

Raphael E Steiner, Steven R Hwang, Arushi Khurana

Pageof 2

Frequent Collaborators

Pallawi Torka

Narendranath Epperla

Reem Karmali

Jonathon B Cohen

Thomas Ollila

Geoffrey Shouse

Leo I Gordon

Ishan Roy

Jason Romancik

Shuo Ma

Frequent Collaborators

Pallawi Torka

Narendranath Epperla

Reem Karmali

Jonathon B Cohen